



Praxis Precision Medicines to Present at Stifel's 3rd Annual CNS Day

March 24, 2021

CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Stifel's 3rd Annual CNS Day on Wednesday, March 31, 2021 at 8:30 a.m. ET.

The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on [LinkedIn](#) and [Twitter](#).

Investor Contact: Alex Kane investors@praxismedicines.com 617-300-8481 Media Contact: Ian Stone Canale
Communications ian.stone@canalecomm.com 619-849-5388